Recent research has brought to light a fascinating aspect of neuroscience that delves into the nuanced differences between male and female brains. Specifically, a study conducted by a team of…
In the realm of pediatric radiology, a newly published study sheds light on the pivotal role of magnetic resonance imaging (MRI) in managing cervicofacial lymphatic malformations. These intricate conditions, characterized…
, /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.,…
, /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief…
, /PRNewswire/ — Lighthouse Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company pioneering precision medicine to address major unmet medical needs, announced a poster presentation at the Clinical Trials on Alzheimer’s Disease…
Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault AI”) common stock in Bitcoin (BTC) (based on the spot…
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate…
Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines. And it’s paying…
Hologic has put forward two studies of its artificial intelligence programs for mammography, showing that an AI tool could maintain high breast cancer detection rates while also simplifying radiologists’ workflows…
The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three months to buy time to review recently submitted information. Having…